Loading...
Loading chart...



The current price of NNNN is 20.65 USD — it has increased 7.05 % in the last trading day.
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Wall Street analysts forecast NNNN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNNN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Anbio Biotechnology revenue for the last quarter amounts to 92.00 USD, increased 38.10 % YoY.
Anbio Biotechnology. EPS for the last quarter amounts to USD, decreased % YoY.
Anbio Biotechnology (NNNN) has 27 emplpoyees as of January 29 2026.
Today NNNN has the market capitalization of 3.00B USD.